Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-amino-azacyclotridecan-2-one
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
3-Amino-azacyclotridecan-2-one is a small molecule belonging to the class of macrolactams—cyclic amides of amino carboxylic acids with a ring size typically larger than ten atoms[2]. It is an experimental compound and has not been approved for any therapeutic use. The mechanism of action involves inhibition of neutrophil collagenase, which suggests potential application in conditions where modulation of this enzyme is desired[2]. There are no known clinical trials or marketed products associated with this compound.
- Other names
- (3S)-3-amino-1-azacyclotridecan-2-one(3S)-3-aminoazacyclotridecan-2-oneDB08476DB-08476DB 08476
02
Targets
MMP8 (Neutrophil collagenase)
Beyond the preview
Go deeper on 3-amino-azacyclotridecan-2-one.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-amino-azacyclotridecan-2-one.